Identification
- Generic Name
- beta-Alanine
- DrugBank Accession Number
- DB03107
- Background
beta-Alanine is an amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, the compound may be a false transmitter replacing GAMMA-AMINOBUTYRIC ACID. A rare genetic disorder, hyper-beta-alaninemia, has been reported.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for beta-Alanine (DB03107)
- Weight
- Average: 89.0932
Monoisotopic: 89.047678473 - Chemical Formula
- C3H7NO2
- Synonyms
- 3-aminopropanoic acid
- 3-aminopropionic acid
- beta-Alanine
- β-alanine
- β-aminopropionic acid
- ω-aminopropionic acid
- External IDs
- FEMA NO. 3252
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UPantothenate synthetase Not Available Mycobacterium tuberculosis - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
Pathway Category Methylmalonic Aciduria Due to Cobalamin-Related Disorders Disease Carnosinuria, Carnosinemia Disease Malonyl-CoA Decarboxylase Deficiency Disease Propanoate Metabolism Metabolic Histidine Metabolism Metabolic Pyrimidine Metabolism Metabolic Histidinemia Disease MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy) Disease beta-Alanine Metabolism Metabolic Aspartate Metabolism Metabolic beta-Ureidopropionase Deficiency Disease Canavan Disease Disease Dihydropyrimidinase Deficiency Disease Hypoacetylaspartia Disease Malonic Aciduria Disease UMP Synthase Deficiency (Orotic Aciduria) Disease GABA-Transaminase Deficiency Disease Ureidopropionase Deficiency Disease - Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Beta amino acids and derivatives
- Alternative Parents
- Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Amine / Amino acid / Beta amino acid or derivatives / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxide
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- beta-amino acid (CHEBI:16958) / Other amino acids, Biogenic amines (C00099)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 11P2JDE17B
- CAS number
- 107-95-9
- InChI Key
- UCMIRNVEIXFBKS-UHFFFAOYSA-N
- InChI
- InChI=1S/C3H7NO2/c4-2-1-3(5)6/h1-2,4H2,(H,5,6)
- IUPAC Name
- 3-aminopropanoic acid
- SMILES
- NCCC(O)=O
References
- Synthesis Reference
Erwin Grill, Ernst-Ludwig Winnacker, Meinhart H. Zenk, "Cysteine-rich peptides having gamma-glutamic acid and beta-alanine units, a process for their preparation and their use." U.S. Patent US4883861, issued March, 1978.
US4883861- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000056
- KEGG Compound
- C00099
- PubChem Compound
- 239
- PubChem Substance
- 46507739
- ChemSpider
- 234
- BindingDB
- 50000102
- 61
- ChEBI
- 57966
- ChEMBL
- CHEMBL297569
- ZINC
- ZINC000004658555
- Therapeutic Targets Database
- DNC000556
- Guide to Pharmacology
- GtP Drug Page
- PDBe Ligand
- BAL
- Wikipedia
- %CE%92-Alanine
- PDB Entries
- 1efr / 1m19 / 1m1a / 1mcd / 1mce / 1mcf / 1mch / 1n2j / 1n2o / 1rgr … show 53 more
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count Not Available Completed Treatment Beta-Alanine / Pelvic Floor Muscle Training / Prostate Cancer / Radical Prostatectomy / Urinary Incontinence (UI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 200 dec °C PhysProp water solubility 5.45E+005 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -3.05 TSAI,RS ET AL. (1991) pKa 3.63 (at 5 °C) KORTUM,G ET AL (1961) - Predicted Properties
Property Value Source Water Solubility 494.0 mg/mL ALOGPS logP -3.3 ALOGPS logP -3.2 Chemaxon logS 0.74 ALOGPS pKa (Strongest Acidic) 4.08 Chemaxon pKa (Strongest Basic) 10.31 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 63.32 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 20.7 m3·mol-1 Chemaxon Polarizability 8.62 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9004 Blood Brain Barrier + 0.7989 Caco-2 permeable - 0.5996 P-glycoprotein substrate Non-substrate 0.7836 P-glycoprotein inhibitor I Non-inhibitor 0.9654 P-glycoprotein inhibitor II Non-inhibitor 0.9572 Renal organic cation transporter Non-inhibitor 0.8567 CYP450 2C9 substrate Non-substrate 0.8728 CYP450 2D6 substrate Non-substrate 0.7638 CYP450 3A4 substrate Non-substrate 0.7882 CYP450 1A2 substrate Non-inhibitor 0.9235 CYP450 2C9 inhibitor Non-inhibitor 0.9508 CYP450 2D6 inhibitor Non-inhibitor 0.9696 CYP450 2C19 inhibitor Non-inhibitor 0.9761 CYP450 3A4 inhibitor Non-inhibitor 0.9583 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9847 Ames test Non AMES toxic 0.8267 Carcinogenicity Non-carcinogens 0.7603 Biodegradation Ready biodegradable 0.9607 Rat acute toxicity 1.1302 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9149 hERG inhibition (predictor II) Non-inhibitor 0.9221
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 109.9640829 predictedDarkChem Lite v0.1.0 [M-H]- 109.7700829 predictedDarkChem Lite v0.1.0 [M-H]- 109.8079829 predictedDarkChem Lite v0.1.0 [M-H]- 129.83815 predictedDeepCCS 1.0 (2019) [M+H]+ 109.6963829 predictedDarkChem Lite v0.1.0 [M+H]+ 109.7237829 predictedDarkChem Lite v0.1.0 [M+H]+ 109.6537829 predictedDarkChem Lite v0.1.0 [M+H]+ 132.60426 predictedDeepCCS 1.0 (2019) [M+Na]+ 109.5434829 predictedDarkChem Lite v0.1.0 [M+Na]+ 109.5371829 predictedDarkChem Lite v0.1.0 [M+Na]+ 109.5027829 predictedDarkChem Lite v0.1.0 [M+Na]+ 140.77133 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Mycobacterium tuberculosis
- Pharmacological action
- Unknown
- General Function
- Catalyzes the condensation of pantoate with beta-alanine in an ATP-dependent reaction via a pantoyl-adenylate intermediate.
- Specific Function
- Atp binding
- Gene Name
- panC
- Uniprot ID
- P9WIL5
- Uniprot Name
- Pantothenate synthetase
- Molecular Weight
- 32677.14 Da
References
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Transporter activity
- Specific Function
- Sodium-independent transporter that mediates the update of aromatic acid. Can function as a net efflux pathway for aromatic amino acids in the basosolateral epithelial cells (By similarity).
- Gene Name
- SLC16A10
- Uniprot ID
- Q8TF71
- Uniprot Name
- Monocarboxylate transporter 10
- Molecular Weight
- 55492.07 Da
References
- Kim DK, Kanai Y, Matsuo H, Kim JY, Chairoungdua A, Kobayashi Y, Enomoto A, Cha SH, Goya T, Endou H: The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics. 2002 Jan;79(1):95-103. [Article]
Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52